FDA's Califf On Real World Evidence: 'Use It For The Right Purposes'
This article was originally published in The Pink Sheet Daily
Commissioner champions data from randomized clinical practice studies to support benefit/risk decisions but also sees value in other types of data generated outside the traditional clinical trial setting.
You may also be interested in...
At his Senate confirmation hearing, Robert Califf said he wants to establish a system, built on electronic medical records, that can be used to more quickly confirm the benefits and risks of accelerated approval drugs.
US FDA Commissioner says that with strong benefit shown, some risks can be discharged postmarket.
Agency seeks candidates for the executive position in charge of its research policy apparatus.